---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-095676"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:03:35.467240+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027

## Summary
- President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.
- CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.
- CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property.

## SEC filing metadata
- accession: 0001104659-25-095676
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/0001104659-25-095676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465925095676/tm2527703d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-095676
- JSON: https://secwatch.observer/filing/0001104659-25-095676.json
- Plain text: https://secwatch.observer/filing/0001104659-25-095676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.